Botulinum Toxin Type B

Total revenues were $219.1 million in the second quarter 2026, a 32% increase compared to same period last year. Combined revenues of the Company's four growth products increased to $175.7 million in the second quarter 2026, representing an increase of 52% compared to the same period last year. This strong growth was driven by an increase in net sales of Qelbree ® , GOCOVRI ® , ZURZUVAE ® , and ONAPGO™. Regulatory submission to the FDA for second supplier for ONAPGO remains on-track for third quarter 2026, with potential approval by mid-year 2027. The Company is raising its full year 2026 financial guidance. Announced today agreement to merge with Indivior Pharmaceuticals, Inc. (Indivior) creating a diversified CNS biopharmaceutical company with significant scale. ROCKVILLE, Md., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced financial results for the second quarter 2026 and associated Company developments. “Our first-half 2026 results reflect the continued strength and sustained momentum of our growth products and continued execution on our commercial strategy,” said Jack Khattar, President and CEO of Supernus. “As we look to the remainder of the year, we remain focused on disciplined execution and prudent capital allocation, and we believe we are well positioned to build on this momentum.” “We are excited about the future of Supernus, even more so following the recent agreement to merge with Indivior Pharmaceuticals, Inc. The combination of these two businesses will form a well-positioned CNS company with a unique pro scale, growth, and flexibility to pursue additional business development opportunities.” Commercial Highlights ezstandalone.cmd.push(function () { ezstandalone.showAds(131); }); ONAPGO net product sales were $13.5 million in the second quarter of 2026. Since the launch in April 2025, and through the end of July 2026, approximately 2,600 enrollment forms have been submitted by approximately 720 prescribers. The Company remains on-track to submit a regulatory filing to the U.S. Food and Drug Administration (FDA) for a second supplier for ONAPGO in the third quarter of 2026, with potential FDA approval by mid-year 2027. Collaboration revenue from ZURZUVAE was $35.4 million in the second quarter of 2026. Collaboration revenue represents 50% of the net revenues for ZURZUVAE recorded by Biogen Inc. Second quarter 2026 U.S sales of ZURZUVAE, as reported by Biogen Inc., increased approximately 53% compared to the same period in 2025. The total number of prescriptions for ZURZUVAE increased by 62% in the second quarter of 2026 compared to the same period last year. Net sales of Qelbree increased 15% to $89.2 million in the second quarter of 2026, compared to the same period in 2025, driven primarily by volume growth. Total IQVIA prescriptions ( 6) for Qelbree were 264,545 for the second quarter 2026, representing an increase of 17% compared to the same period last year. Prescription growth in the adult and pediatric populations was 25% and 14%, respectively. Net sales of GOCOVRI increased 2% to $37.6 million in the second quarter of 2026, compared to the same period in 2025. Total number of prescriptions grew by 9% in the second quarter of 2026 compared to the same period last year. Product Pipeline Update SPN-817 – Novel first-in-class highly selective AChE inhibitor for epilepsy The Phase 2b randomized, double-blind, placebo-controlled study of 3mg and 4mg twice daily doses is ongoing with a targeted enrollment of approximately 258 adult patients with treatment resistant focal seizures. SPN-820 – Novel first-in-class molecule that increases mTORC1 mediated synaptic function for depression The Phase 2b multi-center, randomized, double-blind, placebo-controlled trial in approximately 200 adults with major depressive disorder (MDD). The study will examine the safety and tolerability of SPN-820 2400mg given intermittently (twice weekly) as an adjunctive treatment to the current baseline antidepressant therapy, as well as assess the rapid onset of improvement in depressive symptoms. SPN-443 – Novel stimulant for attention-deficit/hyperactiv ity disorder (ADHD) The Company expects to initiate a Phase 1 single-ascending/multiple-ascending dose study in adult healthy volunteers in the second half of 2026. Financial Highlights This section includes information on non-GAAP financial measures. See "Non-GAAP Financial Information" section for information on non-GAAP financial measures. In addition, a reconciliation of applicable GAAP to non-GAAP financial information is included at the end of this press release. Revenues The following table provides information regarding total revenues (dollars in millions): Three Months Ended June 30, Six Months Ended June 30, 2026 2025 Change % 2026 2025 Change % (unaudited) (unaudited) Net product sales Qelbree $ 89.2 $ 77.6 15% $ 167.1 $ 142.3 17% GOCOVRI 37.6 36.7 2% 72.8 67.4 8% ONAPGO 13.5 1.6 745% 21.9 1.6 1267% Trokendi XR ® 8.4 11.2 (25)% 17.9 24.0 (25)% Oxtellar XR ® 8.8 11.6 (25)% 16.2 21.8 (26)% APOKYN ® 6.3 12.8 (51)% 14.0 27.8 (49)% Other ( 2) 1.9 6.5 (71)% 6.6 15.1 (57)% Total net product sales 165.7 158.0 5% 316.5 300.0 5% Collaboration revenue (ZURZUVAE) (3) 35.4 — 100% 63.0 — 100% Total revenues from commercial products (Non-GAAP) (1) (4) 201.1 158.0 27% 379.5 300.0 27% Royalty, licensing and other revenues ( 5) 18.0 7.5 141% 47.3 15.3 209% Total revenues $ 219.1 $ 165.5 32% $ 426.8 $ 315.3 35% Total revenues from commercial products (non-GAAP) ( 1)(4) represent revenues from our product sales to customers and through our collaboration agreement with Biogen. Other Financial Highlights Operating loss was $58.0 million for the second quarter of 2026, compared to an operating earnings of $12.1 for the same period in 2025. The change was primarily due to a non-cash $54.9 million intangible asset impairment charge related to APOKYN in the second quarter of 2026, an increase in selling, general, and administrative expenses associated with the collaboration agreement with Biogen Inc., partially offset by higher revenues. Adjusted operating earnings (non-GAAP) ( 1) were $31.2 million in the second quarter of 2026, compared to $40.9 million for the same period in 2025. Net loss and diluted loss per share were $58.4 million and $1.01 for the second quarter of 2026, respectively, compared to net earnings and diluted earnings per share of $22.5 million and $0.40 for the same period in 2025. Cash, cash equivalents, and current marketable securities were approximately $372.1 million as of June 30, 2026, compared to $308.7 million as of December 31, 2025. This increase was primarily due to cash generated from operations. Full Year 2026 Financial Guidance The Company is raising its full year 2026 financial guidance as set forth below (dollars in millions): Current Guidance (as of August 4, 2026) Previous Guidance (as of February 24, 2026) Total revenues include the following ( 7) : ONAPGO net sales of $55 million - $70 million Trokendi XR and Oxtellar XR net sales of $50 million - $60 million $860 - $890 $840 - $870 Combined R&D and SG&A expenses $630 - $660 $620 - $650 Operating earnings (loss) $(20) - $(50) $0 - $30 Adjusted operating earnings (non-GAAP) ( 1) $150 - $180 $140 - $170 Non-GAAP Financial Information This press release contains financial measures that present financial information which do not comply with United States generally accepted accounting principles (GAAP). The non-GAAP financial measures should be considered in addition to, not as a substitute for or in isolation from, or superior to measures prepared in accordance with GAAP. Non-GAAP adjusted operating earnings on a historical and projected basis adjusts for non-cash share-based compensation expense, depreciation and amortization, intangible asset impairment charges and changes to fair value of contingent consideration, and for factors that are unusual, non-recurring or unpredictable, and excludes those costs, expenses, and other specified items presented in the reconciliation tables in this press release. We also present total revenues excluding net sales of Trokendi XR (GAAP) and Oxtellar XR (GAAP), which is a non-GAAP measure and is calculated as total revenues (GAAP) less net product sales of Trokendi XR (GAAP) and Oxtellar XR (GAAP). Beginning in the year a product loses exclusivity due to generic entrants, we generally do not expect net product sales of such products to constitute a significant part of our revenue in the future. We also present total revenues from commercial products, which is also a non-GAAP measure and is calculated as the combined total of total net product sales (GAAP) and collaboration revenues (GAAP). We believe that the use of non-GAAP financial measures provides useful supplemental information to management, investors, analysts and others regarding the Company's revenue and results of operations and assist management, investors, analysts, and others in understanding and evaluating our revenue growth and the performance of the business. There are limitations associated with the use of non-GAAP financial measures and therefore comparability may be limited. These limitations include: non-GAAP financial measures that may not be entirely comparable to similarly titled measures used by other companies; these may not reflect all items of income and expense, as applicable, that affect our operations; there may be potential differences among calculation methodologies; these may differ from the non-GAAP information used by other companies, including peer companies. We mitigate these limitations by reconciling the non-GAAP financial measure to the most comparable GAAP financial measure. Investors are encouraged to review the reconciliation. The Company's 2026 financial guidance is also being provided on both a GAAP and a non-GAAP basis. End Notes (1) See the section titled "Non-GAAP Financial Information" for information about this non-GAAP financial measure. A reconciliation of each non-GAAP financial measure to the most directly comparable GAAP financial measure is included at the end of this press release. (2) Includes net product sales of MYOBLOC ® , XADAGO ® and Osmolex ER ® . (3) Represents proportionate share of collaboration revenue from Biogen’s sales of ZURZUVAE to customers in the U.S. from July 31, 2025, the closing of the acquisition of Sage Therapeutics, Inc. (4) Total revenues from commercial products, a non-GAAP measure, represents revenues from our product sales to customers and through our collaboration agreement with Biogen. (5) Royalty, licensing, and other revenues include royalties on generic Trokendi XR, Oxtellar XR, other licensed products and intellectual property. (6) IQVIA data restatement July 1, 2025. (7) Includes net product sales, collaboration revenue, and royalty, licensing, and other revenue. Supernus and Indivior Pharmaceuticals, Inc. to Combine in Merger of Equals In a press release issued on August 3, 2026, it was announced that the Company and Indivior Pharmaceuticals, Inc. have entered into a definitive agreement to combine in an all-stock merger of equals. For more details regarding the agreement and the other transactions contemplated therein (collectively, the Transaction), please review the Company’s Form 8-K filed on August 3, 2026. Transaction Conference Call Details Supernus and Indivior will host a joint conference call to discuss the proposed transaction today, August 3, 2026, at 8:30 a.m. Eastern Time. A live webcast will be available here or from the Investor Relations section of both companies' website at and . Participants are advised to join 10 minutes prior to the scheduled start time. A replay of the webcast will be available following the event. To access the call through a conference line, participants may dial (646) 968-2525 (U.S.) or (888) 596-4144 (toll-free), with the conference ID 3225161. An investor presentation, which will be referenced during the webcast, is also available from the Investor Relations section of both companies' websites. About Supernus Pharmaceuticals, Inc. Supernus Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases. Our diverse neuroscience portfolio includes approved treatments for attention-deficit hyperactivity disorder (ADHD), dyskinesia in Parkinson's disease (PD) patients receiving levodopa-based therapy, hypomobility in PD, postpartum depression (PPD), epilepsy, migraine, cervical dystonia, and chronic sialorrhea. We are developing a broad range of novel product candidates for CNS disorders. For more information, please visit . About Indivior Pharmaceuticals, Inc. As the leader in long-acting injectable treatments for opioid use disorder (OUD), Indivior is singularly focused on delivering evidence-based treatment and advancing understanding of OUD as a chronic but treatable brain disease. For more than 25 years, we have revolutionized the science of addiction medicine, developing treatments that help people move toward long-term recovery with independence and dignity. Building on this heritage, we are ushering in a new era, renewing our commitment to individuals living with OUD and carrying forward what matters most: compassion, integrity, and science. Together – with science, people living with OUD, public health champions, and communities – we are powering recovery and renewing hope. Visit to learn more. Connect with Indivior on LinkedIn by visiting . Forward-Looking Statements This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "anticipate," "believe," "estimate," "expect," "intend," "plan," "project," "may," "will," "would," "could," "should," and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these words. These statements do not convey historical information but relate to predicted or potential future events that are based upon management’s current expectations. These statements are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. In addition to the factors mentioned in this press release, such risks and uncertainties include, but are not limited to, the risk that the proposed merger may not be completed; the possibility that competing offers or acquisition proposals for Supernus or Indivior will be made; the delay or failure of the merger conditions to be satisfied (or waived), including the receipt of required approvals from stockholders of Supernus and Indivior; the failure (or delay) to receive the required regulatory approvals of the proposed merger; the possibility that prior to the completion of the transactions contemplated by the merger agreement, Supernus’s or Indivior’s business may experience significant disruptions due to transaction related uncertainty; the effects of disruption from the transactions on Supernus’s and Indivior’s business and the fact that the announcement and pendency of the transactions may make it more difficult to establish or maintain relationships with employees, manufacturers, suppliers, vendors, business partners and distribution channels to patients; the occurrence of any event, change or other circumstance that could give rise to the termination of the merger agreement; the risk that Supernus may be required to pay a termination fee to Indivior in specified circumstances in which the merger agreement is terminated, and the possibility that the existence of such fee may discourage third parties from proposing an alternative transaction; the risk that stockholder litigation in connection with the proposed transaction may result in significant costs of defense, indemnification and liability; the restrictions on the conduct of Supernus’s business during the pendency of the merger under the interim operating covenants contained in the merger agreement, which may limit Supernus’s ability to pursue business opportunities, make acquisitions or dispositions, incur indebtedness, make capital expenditures, or otherwise take actions it would have taken absent the merger agreement, or to respond to competitive pressures or developments in its industry; the diversion of the attention and resources of Supernus’s management and employees from ongoing business operations and opportunities as a result of the substantial time and effort required to complete the merger and to prepare for integration; the fact that the exchange ratio is fixed and will not be adjusted for changes in the market price of Supernus or Indivior common stock prior to the consummation of the merger, which may decrease the value of the consideration received by Supernus stockholders in connection with the merger; the risk that the anticipated benefits, synergies and cost savings of the merger may not be realized, or may not be realized within the expected timeframe; the difficulties, costs and unanticipated liabilities associated with integrating the businesses, operations, systems, product portfolios and personnel of Supernus and Indivior; the risk that the combined company may be unable to retain and motivate key employees during the pendency of the merger and following its consummation; Supernus’s ability to sustain and increase its profitability; Supernus’s ability to raise sufficient capital to fully implement its corporate strategy; the implementation of Supernus’s corporate strategy; Supernus’s future financial performance and projected expenditures; Supernus’s ability to increase the number of prescriptions written for each of its products, and the products of its subsidiaries; Supernus’s ability to increase its net revenue from its products, and the products of its subsidiaries; Supernus’s ability to commercialize its products, and the products of its subsidiaries; Supernus’s ability to enter into future collaborations with pharmaceutical companies and academic institutions or to obtain funding from government agencies; Supernus’s product research and development activities, including the timing and progress of Supernus’s clinical trials, and projected expenditures; Supernus’s ability to receive, and the timing of any receipt of, regulatory approvals to develop and commercialize Supernus’s product candidates; Supernus’s ability to protect its intellectual property and the intellectual property of its subsidiaries and operate its business without infringing upon the intellectual property rights of others; Supernus’s expectations regarding federal, state and foreign regulatory requirements; the therapeutic benefits, effectiveness and safety of Supernus’s product candidates; the accuracy of Supernus’s estimates of the size and characteristics of the markets that may be addressed by its product candidates; Supernus’s ability to increase its manufacturing capabilities for its products and product candidates; Supernus’s projected markets and growth in markets; Supernus’s product formulations and patient needs and potential funding sources; Supernus’s staffing needs; changes to laws and regulations applicable to the pharmaceuticals industry; the impact of macroeconomic factors, such as economic downturns or uncertainty, international conflict, trade disputes and tariffs; and other risk factors set forth from time to time in Supernus’s and Indivior’s filings with the Securities and Exchange Commission made pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended. Supernus undertakes no obligation to update the information in this press release to reflect events or circumstances after the date hereof or to reflect the occurrence of anticipated or unanticipated events. No Offer or Solicitation This communication is for informational purposes only and does not constitute an offer to sell or the solicitation of an offer to buy any securities or a solicitation of any vote or approval, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offer of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended. Additional Information about the Merger and Where to Find It In connection with the proposed Merger, Indivior intends to the SEC a registration statement on Form S-4 that will include a joint proxy statement of the Company and Indivior that also constitutes a prospectus of Indivior (the “joint proxy statement/prospectus”). Each of the Company and Indivior may also relevant documents with the SEC regarding the proposed Merger. This document is not a substitute for the registration statement, the joint proxy statement/prospectus or any other document that the Company or Indivior may the SEC. The definitive joint proxy statement/prospectus (if and when available) will be mailed to stockholders of the Company and Indivior. INVESTORS AND SECURITY HOLDERS OF THE COMPANY AND INDIVIOR ARE URGED TO READ THE REGISTRATION STATEMENT, THE JOINT PROXY STATEMENT/PROSPECTUS AND ALL OTHER RELEVANT DOCUMENTS THAT ARE FILED OR WILL BE FILED WITH THE SEC, AS WELL AS ANY AMENDMENTS OR SUPPLEMENTS TO THESE DOCUMENTS, CAREFULLY AND IN THEIR ENTIRETY WHEN THEY BECOME AVAILABLE BECAUSE THEY CONTAIN OR WILL CONTAIN IMPORTANT INFORMATION ABOUT THE COMPANY, INDIVIOR AND THE PROPOSED MERGER. Investors and security holders may obtain free copies of the registration statement and the joint proxy statement/prospectus (if and when available) and other documents filed with the SEC by the Company and Indivior through the website maintained by the SEC at Copies of the documents filed with the SEC by the Company will be available free of charge under the “Investor Relations” section of the Company’s website at and copies of the documents filed with the SEC by Indivior will be available free of charge on Indivior’s website. Participants in the Solicitation The Company, Indivior and certain of their respective directors and executive officers may be deemed to be participants in the solicitation of proxies from the stockholders of the Company and Indivior in respect of the proposed Merger. Information regarding the directors and executive officers of the Company, and a description of their direct or indirect interests, by security holdings or otherwise, is set forth in the Company’s proxy statement for its most recent annual meeting of stockholders and its other filings with the SEC. Information regarding the directors and executive officers of Indivior is set forth in Indivior’s comparable filings with the SEC. Additional information regarding the participants in the proxy solicitation and a description of their direct and indirect interests, by security holdings or otherwise, will be contained in the joint proxy statement/prospectus and other relevant materials to be filed with the SEC regarding the proposed Merger when they become available. Free copies of these documents (when available) may be obtained as described in the preceding paragraph. Supernus Pharmaceuticals, Inc. Condensed Consolidated Balance Sheets (in thousands, except share and per share data) June 30, December 31, 2026 2025 (unaudited) Assets Current assets Cash and cash equivalents $ 179,953 $ 128,448 Marketable securities 192,114 180,222 Accounts receivable, net 211,656 187,802 Inventories, net 83,924 82,385 Prepaid expenses and other current assets 55,849 65,325 Total current assets 723,496 644,182 Restricted cash 1,450 1,450 Property and equipment, net 10,197 10,531 Intangible assets, net 469,459 569,456 Goodwill 119,431 124,882 Deferred income tax assets, net 49,061 38,351 Other assets 55,015 63,796 Total assets $ 1,428,109 $ 1,452,648 Liabilities and stockholders' equity Current liabilities Accounts payable and accrued liabilities $ 108,458 $ 107,800 Accrued product returns and rebates 198,844 161,097 Contingent consideration, current portion — 31,052 Other current liabilities 40,076 38,222 Total current liabilities 347,378 338,171 Contingent consideration, long-term 206 206 Operating lease liabilities, long-term 29,427 30,365 Other liabilities 19,872 22,192 Total liabilities 396,883 390,934 Stockholders' equity Common stock, $0.001 par value; 130,000,000 shares authorized; 58,164,352 and 57,457,462 shares issued and outstanding as of June 30, 2026 and December 31, 2025, respectively 58 57 Additional paid-in capital 574,094 543,825 Accumulated other comprehensive loss, net of tax (138 ) (44 ) Retained earnings 457,212 517,876 Total stockholders' equity 1,031,226 1,061,714 Total liabilities and stockholders' equity $ 1,428,109 $ 1,452,648 Supernus Pharmaceuticals, Inc. Condensed Consolidated Statements of Loss (in thousands, except share and per share data) Three Months Ended June 30, Six Months Ended June 30, 2026 2025 2026 2025 (unaudited) (unaudited) Revenues Net product sales $ 165,713 $ 157,995 $ 316,466 $ 299,983 Collaboration revenue (ZURZUVAE) 35,350 — 62,993 — Royalty, licensing, and other revenues 17,995 7,458 47,304 15,294 Total revenues 219,058 165,453 426,763 315,277 Costs and expenses Cost of revenues (a) 33,669 16,827 57,060 32,590 Research and development 29,463 22,115 68,901 49,042 Selling, general and administrative 133,637 93,551 258,810 183,495 Amortization of intangible assets 25,333 20,819 50,977 40,605 Intangible asset impairment charges 54,919 — 54,919 — Contingent consideration loss — — 2,391 7,660 Total costs and expenses 277,021 153,312 493,058 313,392 Operating earnings (loss) (57,963 ) 12,141 (66,295 ) 1,885 Other income (expense) Interest and other income, net 2,630 4,528 5,012 8,953 Interest expense (2,315 ) — (2,315 ) — Total other income, net 315 4,528 2,697 8,953 Earnings (loss) before income taxes (57,648 ) 16,669 (63,598 ) 10,838 Income tax expense (benefit) 723 (5,830 ) (2,934 ) 166 Net earnings (loss) $ (58,371 ) $ 22,499 $ (60,664 ) $ 10,672 Earnings (loss) per share Basic $ (1.01 ) $ 0.40 $ (1.05 ) $ 0.19 Diluted $ (1.01 ) $ 0.40 $ (1.05 ) $ 0.19 Weighted average shares outstanding Basic 58,070,378 56,024,771 57,860,131 55,945,434 Diluted 58,070,378 56,643,189 57,860,131 56,688,754 (a) Excludes amortization of intangible assets. Supernus Pharmaceuticals, Inc. Reconciliations of GAAP to Non-GAAP Financial Information (unaudited) Reconciliation of GAAP Total revenues to Non-GAAP Total revenues excluding Trokendi XR and Oxtellar XR net sales An itemized reconciliation between total revenues on a GAAP basis and total revenues excluding Trokendi XR and Oxtellar XR net sales, a non-GAAP measure, is as follows (dollars in millions): Three Months Ended June 30, Six Months Ended June 30, 2026 2025 Change % 2026 2025 Change % Total revenues (GAAP) (a) $ 219.1 $ 165.5 32% $ 426.8 $ 315.3 35% Adjustments: Trokendi XR net product sales (8.4 ) (11.2 ) (25)% (17.9 ) (24.0 ) (25)% Oxtellar XR net product sales (8.8 ) (11.6 ) (24)% (16.2 ) (21.8 ) (26)% Total revenues excluding Trokendi XR and Oxtellar XR net sales (non-GAAP) $ 201.9 $ 142.7 41% $ 392.7 $ 269.5 46% (a) Includes net product sales, collaboration revenue, and royalty, licensing, and other revenues. Reconciliation of GAAP Net Product Sales to Non-GAAP Revenues from Commercial Products An itemized reconciliation between Net product sales on a GAAP basis and total revenues from commercial products, a non-GAAP measure, is as follows (dollars in millions): Three Months Ended June 30, Six Months Ended June 30, 2026 2025 Change % 2026 2025 Change % Net product sales (GAAP) $ 165.7 $ 158.0 5% $ 316.5 $ 300.0 6% Adjustments: Collaboration revenue (ZURZUVAE) 35.4 — 100% 63.0 — 100% Total revenues from commercial products $ 201.1 $ 158.0 27% $ 379.5 $ 300.0 27% Total revenues from commercial products, a non-GAAP measure, represents revenues from our product sales to customers and through our collaboration agreement with Biogen. Reconciliation of GAAP Operating Earnings (Loss) to Non-GAAP Adjusted Operating Earnings An itemized reconciliation between operating earnings (loss) on a GAAP basis and adjusted operating earnings on a non-GAAP basis is as follows (dollars in millions): Three Months Ended June 30, Six Months Ended June 30, 2026 2025 2026 2025 Operating earnings (loss) - As Reported (GAAP) $ (58.0 ) $ 12.1 $ (66.3 ) $ 1.9 Adjustments: Amortization of intangible assets 25.3 20.8 51.0 40.6 Intangible asset impairment charges 54.9 — 54.9 — Share-based compensation 8.6 7.5 17.1 15.6 Contingent consideration loss (gain) — — 2.4 7.7 Depreciation 0.4 0.5 0.9 1.1 Operating earnings - As Adjusted (non-GAAP) $ 31.2 $ 40.9 $ 60.0 $ 66.9 Non-GAAP adjusted operating earnings adjusts for non-cash items, which include amortization of intangible assets, share-based compensation expense, change in fair value of contingent consideration, depreciation, and intangible asset impairment charges. Reconciliation of Full Year 2026 Financial Guidance - GAAP Operating Earnings (Loss) to Non-GAAP Adjusted Operating Earnings An itemized reconciliation between projected operating earnings (loss) on a GAAP basis for the full year 2026 and projected adjusted operating earnings on a non-GAAP basis for the full year 2026 is as follows (dollars in millions): Current Guidance (as of August 4, 2026) Previous Guidance (as of February 24, 2026) Operating earnings (loss) - GAAP $(20) - $(50) $0 - $30 Adjustments: Amortization of intangible assets $97 $105 Intangible asset impairment charges $55 $— Share-based compensation $35 $35 Contingent consideration loss $2 $2 Depreciation $3 $3 Operating earnings - As Adjusted (non-GAAP) $150 - $180 $140 - $170 CONTACTS: Jack A. Khattar, President and CEO Timothy C. Dec, Senior Vice President and CFO Supernus Pharmaceuticals, Inc. (301) 838-2591 or INVESTOR CONTACT: Peter Vozzo ICR Healthcare (443) 213-0505 peter.vozzo@icrhealthcare.com

Boey® is the first and only rapid-onset and short-duration botulinum neurotoxin serotype E approved in Europe that adult patients can try for the temporary improvement of glabellar lines¹ Results may be seen as early as eight hours after treatment and typically wear off within approximately two to three weeks Boey® offers a differentiated treatment option for many people who are curious about facial injectables² NORTH CHICAGO, Ill., July 17, 2026 /PRNewswire/ -- Allergan Aesthetics, an AbbVie company (NYSE: ABBV), announced the European Commission has approved Boey® (trenibotulinumtoxinE) in Europe, for the temporary improvement in the appearance of moderate to severe lines between the eyebrows seen at maximum frown (glabellar lines) in adult patients, when these have an important psychological impact.1 Following completion of the centralized procedure, the European Commission decision applies across all 30 European Economic Area (EEA) countries. Boey® also received approval in Canada in June of this year. Boey® is the first and only rapid-onset and short-duration botulinum neurotoxin serotype E approved in Europe. In clinical studies, onset of effect was observed as early as eight hours after treatment and effects lasted two to three weeks. "The EU approval of Boey® marks an important step forward for our development program and builds on the momentum we've established with Health Canada's approval earlier this year," said Darin Messina, Ph.D., senior vice president, aesthetics research & development, AbbVie. "This milestone reflects the scientific rigor behind Boey® and reinforces our commitment to advancing innovative options as we work to bring this first-of-its-kind treatment to healthcare professionals and consumers around the world." As interest in aesthetic treatments continues to grow, patients are increasingly seeking treatment options that align with their individual goals and preferences. An Allergan Aesthetics survey found that 80% of people are open to learning about new treatments to achieve their desired results, while 79% wish they could temporarily preview the outcome of an aesthetic treatment.3,* Despite this growing interest, many patients remain hesitant to take the next step due to uncertainty around treatment outcomes and concerns about committing to long-lasting results. Boey® was developed for patients considering treatment, offering another option to experience it before making a longer-term commitment. Developed by the makers of BOTOX Cosmetic®, known as VISTABEL® or Vistabex® in the EU, Boey® offers a new option for suitable patients considering facial injectables. BOTOX Cosmetic® is the only neurotoxin clinically tested for safety following treatment with Boey®.1 Allergan Aesthetics is preparing to launch Boey® across Europe and will support healthcare professionals through education and training on the appropriate use of Boey®. Allergan Aesthetics develops, manufactures and markets a portfolio of leading aesthetics brands and products. Allergan Aesthetics is well positioned to lead the future of injectable aesthetics, with dedicated research and development focused on driving innovation to meet the evolving needs of patients and healthcare professionals worldwide. BOTOX ® COSMETIC US APPROVED USES AND IMPORTANT SAFETY INFORMATION BOTOX® Cosmetic is a prescription medicine that is injected into muscles and used to temporarily improve the look of moderate to severe forehead lines, crow's feet lines, frown lines between the eyebrows, and vertical bands connecting the jaw and neck (platysma bands) in adults. IMPORTANT SAFETY INFORMATION BOTOX ® Cosmetic may cause serious side effects that can be life threatening. Get medical help right away if you have any of these problems any time (hours to weeks) after injection of BOTOX® Cosmetic: Problems swallowing, speaking, or breathing, due to weakening of associated muscles, which can be severe and result in loss of life. You are at the highest risk if these problems are preexisting before injection. Swallowing problems may last for several months. Spread of toxin effects. The effect of botulinum toxin may affect areas away from the injection site and cause serious symptoms, including loss of strength and all-over muscle weakness, double vision, blurred vision and drooping eyelids, hoarseness or change or loss of voice, trouble saying words clearly, loss of bladder control, trouble breathing, and trouble swallowing. BOTOX ® Cosmetic dosing units are not the same as, or comparable to, any other botulinum toxin product. There has not been a confirmed serious case of spread of toxin effect when BOTOX® Cosmetic has been used at the recommended dose to treat frown lines, crow's feet lines, forehead lines, and/or platysma bands. BOTOX® Cosmetic may cause loss of strength or general muscle weakness, vision problems, or dizziness within hours to weeks of receiving BOTOX® Cosmetic. If this happens, do not drive a car, operate machinery, or do other dangerous activities. Serious and/or immediate allergic reactions have been reported, including itching, rash, red itchy welts, wheezing, asthma symptoms, or dizziness or feeling faint. Get medical help right away if you are wheezing or have asthma symptoms, or if you become dizzy or fain. Do not receive BOTOX® Cosmetic if you are allergic to any of the ingredients in BOTOX® Cosmetic (see Medication Guide for ingredients); had an allergic reaction to any other botulinum toxin product such as Myobloc (rimabotulinumtoxinB), Dysport (abobotulinumtoxinA), Xeomin (incobotulinumtoxinA), Jeuveau (prabotulinumtoxinA-xvfs), Daxxify (daxibotulinumtoxinA-lanm), or Letybo (letibotulinumtoxinA-wlbg); or have a skin infection at the planned injection site. This list may not include all available botulinum toxin products. Tell your doctor about all your muscle or nerve conditions, such as ALS or Lou Gehrig's disease, myasthenia gravis, or Lambert-Eaton syndrome, as you may be at increased risk of serious side effects, including difficulty swallowing and difficulty breathing, from standard doses of BOTOX® Cosmetic. Tell your doctor about all your medical conditions, including surgery or plans to have surgery on your face, trouble raising your eyebrows, drooping eyelids, any other abnormal facial change, are pregnant or plan to become pregnant (it is not known if BOTOX® Cosmetic can harm your unborn baby), or are breastfeeding or plan to (it is not known if BOTOX® Cosmetic passes into breast milk). Tell your doctor about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Using BOTOX® Cosmetic with certain other medicines may cause serious side effects. Do not start any new medicines until you have told your doctor that you have received BOTOX ® Cosmetic in the past. Tell your doctor if you have received any other botulinum toxin product in the last 4 months; have received injections of botulinum toxin such as Myobloc, Dysport, Xeomin, Jeuveau, Daxxify, or Letybo in the past (tell your doctor exactly which product you received); have recently received an antibiotic by injection; take muscle relaxants; take an allergy or cold medicine; take a sleep medicine; or take aspirin-like products or blood thinners. Other side effects of BOTOX ® Cosmetic include dry mouth; discomfort or pain at the injection site; tiredness; headache; neck pain; and eye problems, including double vision, blurred vision, decreased eyesight, drooping eyelids and eyebrows, swelling of eyelids, and dry eyes. For more information, refer to the Medication Guide or talk with your doctor. To report a side effect, please call Allergan Aesthetics at 1-800-678-1605. Please see BOTOX ® Cosmetic full US Product Information , including Boxed Warning and Medication Guide . About Boey ® Boey® is a facial injectable neurotoxin serotype E that targets SNAP-25. It has a rapid uptake and translocation into neuronal cells, with a short half-life of the type E light chain, giving it a rapid onset of action and a short duration of effect when treating glabellar lines. About Boey ® Clinical Trials The approval of Boey® is supported by data from two randomised, multi-centre, double-blind, placebo-controlled studies Phase 3 clinical trials evaluating the efficacy and safety of Boey® in adults with moderate to severe glabellar lines (M21-500 and M21-508) associated with corrugator and/or procerus muscle activity, who were psychologically impacted by their glabellar lines. The studies enrolled 725 patients treated with Boey® 700 U total dose or placebo. The co-primary efficacy measure (treatment effect) was defined as the percentage of subjects achieving a ≥2-grade improvement from baseline in glabellar line severity at maximum frown based separately on investigator and subject assessments using the 4-point Facial Wrinkle Scale (FWS) (0=none, 1=mild, 2=moderate, 3=severe) at Day 7. Efficacy was assessed in the ITT population with baseline FLO-11 Total Transformed Score of ≤50. Secondary efficacy endpoints were measured by FLSQ, a scale developed by Allergan Aesthetics, and included satisfaction with achieving a natural look (Item 4) and overall satisfaction with treatment effect (Item 5). The onset of effect for patients treated with Boey® appeared as early as 8 hours after injection in both pivotal studies. The peak effect was seen at Day 7 in both studies. Glabellar lines returned to baseline severity in approximately 2 to 3 weeks after administration. The adverse drug reactions associated with Boey® were eyelid ptosis, brow ptosis, and Mephisto sign (lateral elevation of eyebrow). These reactions were reported in 0.17%, 0.13%, and 0.04%, respectively, in subjects receiving Boey® 700 units.1 About Glabellar Lines Glabellar lines are the vertical lines that appear between the eyebrows, commonly known as frown lines. In some adults, these lines can contribute to an appearance that is perceived as tired, angry or worried and may have an important psychological impact. About Allergan Aesthetics At Allergan Aesthetics, an AbbVie company, we develop, manufacture, and market a portfolio of leading aesthetics brands and products. Our aesthetics portfolio includes facial injectables, body contouring, plastics, skin care, and more. Our goal is to consistently provide our customers with innovation, education, exceptional service, and a commitment to excellence, all with a personal touch. For more information, visit About AbbVie AbbVie's mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas including immunology, neuroscience and oncology – and products and services in our Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at . Follow @abbvie on LinkedIn, Facebook, Instagram, X and YouTube. Forward-Looking Statements Some statements in this news release are, or may be considered, forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. The words "believe," "expect," "anticipate," "project" and similar expressions and uses of future or conditional verbs, generally identify forward-looking statements. AbbVie cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those expressed or implied in the forward-looking statements. Such risks and uncertainties include, but are not limited to, challenges to intellectual property, competition from other products, difficulties inherent in the research and development process, adverse litigation or government action, changes to laws and regulations applicable to our industry, the impact of global macroeconomic factors, such as economic downturns or uncertainty, international conflict, trade disputes and tariffs, and other uncertainties and risks associated with global business operations. Additional information about the economic, competitive, governmental, technological and other factors that may affect AbbVie's operations is set forth in Item 1A, "Risk Factors," of AbbVie's 2025 Annual Report on Form 10-K, which has been filed with the Securities and Exchange Commission, as updated by its Quarterly Reports on Form 10-Q and in other documents that AbbVie subsequently files with the Securities and Exchange Commission that update, supplement or supersede such information. AbbVie undertakes no obligation, and specifically declines, to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law. Footnotes *Customer survey research carried out across nine countries that included online data collection and a 20-minute self-administered closed questionnaire conducted between November to December 2025. 12,286 participants (Brazil 1,318, Canada 1,304, China 1,318, France 1,302, Germany 1,301, KSA 1,311, Thailand 1,321, USA 1,802 and UK 1,309) who have paid for at least two beauty or aesthetics-related services in the past year References Boey® Summary of Product Characteristics. AbbVie Ltd Allergan Aesthetics Holistic Beauty Global Research. REF-148616. January 2026. Allergan Aesthetics Holistic Beauty Global Research. REF-148616. January 2026. SOURCE AbbVie 21% more press release views with Request a Demo